Accueil » Archives pour Paulo Martins » Page 7

Author: Paulo Martins

Prostate Cancer Leads Aerospace Biomedical Technician to Discover High-Tech HIFU

MedmavenCancerConnect

So, at age 58, when I was diagnosed with prostate cancer I was determined to get it taken care of, and hold on to my quality of life in the process.

In those explorations, I ultimately discovered a medical procedure called HIFU, which is shorthand for High Intensity Focused Ultrasound. Essentially, with HIFU, the doctor directs high-frequency sound waves to heat up and burn off diseased tissue in the prostate using an ultrasound probe. As I found in my research, this approach has been shown to result in reduced side effects like impotence and incontinence, according to some studies in Europe and elsewhere in the world.

A New Treatment for Localized Prostate Cancer Lets Men Keep the Sexual Passion in Their Relationships

Dr. Cary N. Robertson MD. Medically reviewed by Dr. C.H. Weaver, MD.WOMEN Magazine

In the years since the first North American clinical trial to evaluate its safety and effectiveness, High Intensity Focused Ultrasound (HIFU) has emerged as a viable procedure for patients to consider after receiving a diagnosis of localized prostate cancer.

That study, begun in 2007 and known as the Enlight Trial, examined the efficacy of HIFU in participating patients diagnosed with low grade, low volume prostate cancer. In 2015, the FDA cleared transrectal ultrasound guided HIFU as a surgical tool for prostate tissue ablation. Around the world, more than 45,000 patients have undergone the prostate HIFU procedure.

Who is a Candidate for HIFU Treatment for Prostate Cancer

Dr. Cary N. Robertson, MD. Medically reviewed by Dr. C.H. Weaver MDCancerConnect

In the years since the first North American clinical trial to evaluate its safety and effectiveness, High Intensity Focused Ultrasound (HIFU) has emerged as a viable procedure for patients to consider after receiving a diagnosis of localized prostate cancer.

That study, begun in 2007 and known as the Enlight Trial, examined the efficacy of HIFU in participating patients diagnosed with low grade, low volume prostate cancer. In 2015, the FDA cleared transrectal ultrasound guided HIFU as a surgical tool for prostate tissue ablation. Around the world, more than 45,000 patients have undergone the prostate HIFU procedure.

A Doctor And His Patient On The Benefits Of A More Effective Surgery

JOHN L. HANSON JR.KUT 90.5 – Austin’s NPR Station

On this edition of In Black America, producer/host John L. Hanson Jr. speaks with Dr. Brian J. Miles, board-certified urologist with Houston Methodist Hospital and Victor Murray, a prostate cancer patient.

Each year more than 200,000 men are diagnosed with prostate cancer, with most cases affecting African-American men 65 and older.

Dr. Miles and Murray talk about prostate cancer and how less invasive procedure to treat it is cutting down on recovery times.

Alternative Treatment for Localized Prostate Cancer: Three Men’s Perspectives

goodmenproject

Prostate cancer is the most common cancer among men, after skin cancer. According to the American Cancer Society, there will be more than 161,000 new diagnoses this year alone. For decades men suffering from prostate cancer have had two primary modalities for treating prostate cancer.

Prostate cancer is the most common cancer among men, after skin cancer. According to the American Cancer Society, there will be more than 161,000 new diagnoses this year alone. For decades men suffering from prostate cancer have had two primary modalities for treating prostate cancer:

(1) Watchful waiting or active surveillance

(2) Radical treatment

Thanks to advances in ultrasound technology, however, men have another option: High Intensity Focused Ultrasound (HIFU). Three men tell their stories about why they chose HIFU…

Less-invasive prostate cancer treatment receives FDA clearance

512tech

Prostate cancer patients around the country will soon have a less-invasive, radiation-free treatment option. 

French company EDAP TMS, which made Austin its U.S. headquarters two years ago, has received U.S. Food and Drug Administration clearance for “Focal One” — a treatment for prostate cancer using high-intensity focused ultrasound. 

Brian Miles, a urologist at Houston’s Methodist Hospital, said the facility is aiming to be the first U.S. site to house the technology. 

“I see this being embraced substantially in Texas now that Focal One has been accepted,” he said. “I think it will really become a standard therapy.” 

Miles said Focal One allows him to destroy a targeted area rather than remove the entire prostate, which can increase the risk of side effects like erectile dysfunction and urinary incontinence. Men with localized prostate cancer, meaning only contained in the prostate, are eligible for the procedure. 

“The Focal One device by comparison will allow me to take a mouse and outline the area that I want treated,” Miles said, adding that the machine then takes over. 

According to the U.S. Centers for Disease Control, prostate cancer is the leading cancer diagnosed in men each year in the country. 

Prostate cancer patients in the U.S. can already access high-intensity focused ultrasound treatments similar to Focal One, but the method is often costly and not well-known, Miles said. The two focused ultrasound systems approved in the U.S. for destruction of prostate tissue are EDAP’s first generation Ablatherm and now Focal One and SonaCare’s Sonablate. 

Sonablate and Ablatherm received FDA approval in 2015.

Study Confirms HIFU’s Safety, Efficacy and Benefits for Patients’ Quality of Life

DR. BRUNO NAHARFORWARD Florida

Prostate cancer is the second most common cancer among men, behind skin cancer. About 1 in 9 men will be diagnosed with this disease during his lifetime. Here at the University of Miami Miller School, we conducted the first U.S. clinical cohort study with 50 patients using the Ablatherm Robotic HIFU (High Intensity Focused Ultrasound) system for treatment of early stage prostate cancer. The results were very promising, and the study is on going as we continue to enroll patients.

For decades men suffering from prostate cancer have had two primary choices for treatment – radiation therapy or radical surgery to remove the entire prostate – both of which cause life-altering side effects of impotence or incontinence. HIFU, the result of advances in ultrasound technology, is a noninvasive procedure that directs high-frequency sound waves to ablate prostate tissue, with a low risk of the side effects associated with traditional treatments.

Study Confirms HIFU’s Safety, Efficacy and Benefits for Patients’ Quality of Life

Preliminary results of the study demonstrated promising oncological short-term outcomes, even in clinically significant prostate cancer.

All patients who participated had been diagnosed with localized prostate cancer, cancer that has not spread beyond the prostate gland, and were eligible for focal HIFU therapy.

As noted, the treatment options before HIFU – radiation or surgery – caused significant physical side effects, and the only other possibility took an emotional toll. Doctors sometimes would employ what was known as “watchful waiting,” or “active surveillance.” For patients diagnosed with a low-risk disease, this “wait-and-see” option involved urologists monitoring the patient over time, since prostate cancer is slow growing. Though medically valid, it was stressful for patients with active cancer and many ultimately preferred more aggressive treatment options despite the side effects.